What was recalled
This page synthesizes the regulatory and evidence framework around Enterococcus faecium strain SF68 (NCIMB 10415) in commercial veterinary probiotics and pet food. SF68 was originally isolated by Cerbios-Pharma SA in Switzerland in the 1970s from a fermentation source and deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB) under accession 10415. The strain has been commercialized for human use (Cylactin and similar products in Europe) and for veterinary use (Purina FortiFlora in North America, in licensing partnership between Nestlé Purina and Cerbios-Pharma). The strain has been genomically characterized and shown to lack the major virulence factors (esp, hyl, asa1, cylA) and vancomycin resistance genes (vanA, vanB) that distinguish concerning hospital-acquired E. faecium strains. The strain genome has been deposited and is publicly accessible for safety-genomic review.
The companion-animal evidence base for SF68 spans approximately 30+ published peer-reviewed trials in dogs and cats over a 20+ year window. Key trial findings include: (i) Marshall-Jones 2006 J Vet Intern Med — healthy adult dogs (n=15), 4-week supplementation, documented increase in peripheral blood lymphocyte proliferation, reduced fecal Clostridium counts; (ii) Benyacoub 2003 J Nutr — puppies (n=20), documented increased fecal IgA secretion and improved vaccine response; (iii) Bybee 2011 J Vet Intern Med — shelter cats (n=217 in probiotic arm, n=212 in placebo arm), documented reduced diarrhea incidence (7.4% vs 20.7%), primary endpoint clinically and statistically significant; (iv) Lappin 2009 J Feline Med Surg — chronic feline herpesvirus-1 cats (n=12), documented reduced clinical signs during stress-induced viral recrudescence; (v) Kelley 2009 Vet Ther — dogs with idiopathic acute diarrhea (n=31), documented reduced time to stool normalization; (vi) Herstad 2010 J Small Anim Pract — dogs with acute gastroenteritis (n=36), documented reduced duration of clinical signs. The trial dataset includes multiple double-blinded placebo-controlled designs and meta-analytic synthesis.
The regulatory framework around SF68 includes: (i) FDA Generally Recognized As Safe (GRAS) notice for the strain; (ii) AAFCO defined-ingredient inclusion under "dried Enterococcus faecium fermentation product"; (iii) EU specific authorization for animal feed use as Cylactin LBC-IF; (iv) Swiss Federal Office of Public Health authorization for human use. The framework is unusual in pet food probiotics because the strain-specific evidence and regulatory authorization is substantial enough that the strain is treated as a defined ingredient rather than a generic species-level addition.
Why it was recalled
The structural concerns have three layers. Layer one — genus-level Enterococcus pathogenicity concerns require product-level vigilance: the Enterococcus genus is the third most common cause of hospital-acquired bacterial infection in human medicine, with vancomycin-resistant Enterococcus (VRE) being a major nosocomial pathogen. Genus-level concerns include intrinsic and acquired antibiotic resistance, virulence factor expression, and opportunistic pathogenicity in immunocompromised hosts. The framework gap is that commercial pet food products listing "Enterococcus faecium" at the species level on the label may include strains that are not SF68 and may not have undergone the same genomic safety characterization. The framework places confidence in the SF68 strain specifically rather than the genus generally.
Layer two — the strongest companion-animal probiotic evidence base creates an evidence-asymmetry between SF68 and other commercial strains: the SF68 evidence base (~30 published companion-animal trials) is substantially deeper than the companion-animal evidence base for any other commercial probiotic strain. Brands marketing alternative strains often cite cross-species (human) evidence to support equivalent efficacy claims, which is not scientifically supported. The framework asymmetry should drive veterinary recommendation patterns toward SF68 for specific therapeutic goals (acute diarrhea, immunomodulation, post-antibiotic recovery), with awareness that the SF68 evidence does not transfer to other Enterococcus or Lactobacillus strains.
Layer three — CFU dose-response is meaningful for SF68 specifically: SF68 clinical trials typically use doses of 5x10^8 to 5x10^9 CFU/day for dogs and cats. Commercial FortiFlora packets deliver approximately 1x10^8 CFU per packet, which provides therapeutic dosing for cats and adjunct dosing for dogs. Pet food formulations including SF68 at the 10^6 to 10^7 CFU/g of food level may not achieve therapeutic dosing depending on daily food intake. The framework gap is that consumer-facing products rarely communicate the dose-response framework or the difference between baseline gut-health-support dosing and therapeutic dosing.
Health risks for your pet
SF68 safety profile in companion animals is favorable based on the ~30 published trials, with no documented serious adverse events at typical clinical dosing (5x10^8 to 5x10^9 CFU/day). The strain lacks major virulence factors and vancomycin resistance genes that distinguish concerning E. faecium strains. Theoretical safety considerations for any Enterococcus strain include: (i) bacteremia in severely immunocompromised animals (rare; severely neutropenic chemotherapy patients and post-transplant patients in human medicine have documented occasional Enterococcus bacteremia from probiotic strains, though SF68 specifically has minimal documented cases); (ii) horizontal gene transfer of antibiotic resistance to other gut microbiota (theoretical concern requiring continued safety monitoring; SF68 lacks the conjugative plasmids associated with vancomycin resistance transfer); (iii) modest transient stool changes during initial supplementation (common; resolves 1-2 weeks); (iv) interaction with concurrent antibiotic therapy (CFU drops substantially during antibiotic courses).
The clinical-context concerns are minimal for routine use. Veterinary literature and clinical practice generally recommends SF68 for acute idiopathic diarrhea (most common indication), stress-related GI upset, post-antibiotic recovery, chronic enteropathy management (as adjunct to dietary management), and immune support in puppies and kittens. Contraindications are limited to severely immunocompromised animals (chemotherapy, transplant, severe immunosuppression) where any live probiotic should be considered carefully.
What to do if you bought affected product
Pet owners can use SF68-containing products meaningfully through several practical approaches: (1) recognize FortiFlora as the canonical SF68 product — Purina Pro Plan Veterinary Diets FortiFlora is the most-prescribed veterinary probiotic in North America and contains SF68 at therapeutic dose (10^8 CFU/packet); (2) use SF68 for specific therapeutic indications — acute idiopathic diarrhea, stress-related GI upset, post-antibiotic recovery, and immune support in puppies/kittens carry the strongest evidence; (3) distinguish SF68 from generic Enterococcus faecium — pet food labels listing "Enterococcus faecium" at the species level may or may not contain SF68; contact brand customer service to confirm strain identity if specific evidence quality matters; (4) understand the dose framework — therapeutic dosing for SF68 is 5x10^8 to 5x10^9 CFU/day; FortiFlora packets deliver ~10^8 CFU each, with 1-2 packets/day typical for cats and 1-3 packets/day for dogs depending on size; baseline probiotic-fortified kibble at 10^6-10^7 CFU/g may or may not deliver therapeutic dose depending on daily food intake; (5) monitor for clinical improvement within 1-2 weeks — if acute diarrhea or stress-related GI upset does not improve with SF68 supplementation, consult with your veterinarian; (6) consider SF68 for chronic enteropathy adjunctive management — chronic enteropathy benefits from dietary management as primary intervention; SF68 supplementation as adjunct is supported by several trials but should be used in coordination with a veterinarian; (7) do not use SF68 in severely immunocompromised animals without veterinary consultation — chemotherapy, organ transplant, and severe immunosuppression contexts require individual risk-benefit analysis; (8) treat SF68 evidence as strain-specific — the documented effects in dogs and cats apply to SF68 specifically and do not transfer to other commercial probiotic strains.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate SF68 inclusion from other Enterococcus faecium strain inclusion per our published methodology, since strain identity is rarely disclosed on pet food labels. Future rubric extension under consideration: brands publishing SF68 NCIMB 10415 strain identification with CFU-at-end-of-shelf-life guarantee would receive favorable scoring weight as evidence-quality and transparency signal. SF68 inclusion at therapeutic CFU level (5x10^8+ per recommended daily feeding) represents one of the strongest probiotic ingredient choices in pet food. Related framework coverage is across our Enterococcus faecium explainer, probiotic strain viability controversy, and the multi-strain probiotic framework documented across BB-12 evidence and L. acidophilus evidence. For now, our recommendation: treat SF68 specifically as the strongest evidence-supported probiotic for companion animals, with awareness that the evidence applies to SF68 (NCIMB 10415) and does not transfer to other Enterococcus strains.